Jazz Pharmaceuticals PLC (JAZZ) — 8-K Filings

8-K Filings (27)

• Jazz Pharmaceuticals Files 8-K — Nov 17, 2025 Risk: low
  On November 17, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material e
• Jazz Pharmaceuticals Announces Executive and Board Changes — Oct 28, 2025 Risk: medium
  Jazz Pharmaceuticals plc announced on October 23, 2025, changes in its executive team and board of directors. The filing details the departure of certain office
• Jazz Pharmaceuticals Files 8-K Report — Oct 22, 2025 Risk: low
  On October 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing indicates that the company is located at Fifth Floor, Waterloo Exchange, Waterloo
• Jazz Pharmaceuticals Files 8-K on Financials — Aug 5, 2025 Risk: low
  On August 5, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Jazz Pharmaceuticals Schedules Shareholder Vote — Jul 25, 2025 Risk: medium
  On July 24, 2025, Jazz Pharmaceuticals plc filed an 8-K report to announce a submission of matters to a vote of security holders. The filing was made public on
• Jazz Pharma Announces Executive Changes — Jul 10, 2025 Risk: medium
  Jazz Pharmaceuticals plc announced on July 8, 2025, changes in its executive team, including the appointment of a new Chief Medical Officer, Dr. Robert I. Smith
• Jazz Pharmaceuticals Files 8-K on Financials — May 6, 2025 Risk: low
  On May 6, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
• Jazz Pharmaceuticals Files 8-K Report — Apr 21, 2025 Risk: low
  On April 21, 2025, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• Jazz Pharmaceuticals Enters Material Definitive Agreement — Apr 8, 2025 Risk: medium
  On April 7, 2025, Jazz Pharmaceuticals plc entered into a material definitive agreement. The company, incorporated in Ireland with its principal executive offic
• Jazz Pharmaceuticals Files 8-K on Financials — Feb 25, 2025 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on February 25, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Jazz Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
  On January 13, 2025, Jazz Pharmaceuticals plc (JAZZ) filed a Form 8-K to report its status as a public company. The filing confirms the company's incorporation
• Jazz Pharmaceuticals Appoints New Chief Medical Officer and CLO — Dec 16, 2024 Risk: low
  On December 11, 2024, Jazz Pharmaceuticals plc announced changes to its executive team. The company appointed two new officers: Dr. Robert I. Tepper as Chief Me
• Jazz Pharmaceuticals Enters Material Definitive Agreement — Nov 26, 2024 Risk: medium
  On November 26, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Jazz Pharmaceuticals Files 8-K Report — Nov 21, 2024 Risk: low
  On November 20, 2024, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
• Jazz Pharmaceuticals Files 8-K on Financials — Nov 6, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and e
• Jazz Pharmaceuticals Terminates Material Definitive Agreement — Oct 16, 2024 Risk: medium
  Jazz Pharmaceuticals plc announced on October 10, 2024, the termination of a material definitive agreement. The filing does not specify the other party involved
• Jazz Pharmaceuticals Reports Key Financial and Corporate Events — Sep 6, 2024 Risk: medium
  On September 3, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to its financing. The company also reported on the creation
• Jazz Pharma Closes $1B Senior Notes Offering, Secures New Credit Facility — Aug 28, 2024 Risk: low
  On August 27, 2024, Jazz Pharmaceuticals plc announced the closing of its previously disclosed offering of $1.0 billion aggregate principal amount of 5.000% sen
• Jazz Pharmaceuticals Files 8-K on Financials — Jul 31, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Jazz Pharmaceuticals Holds Shareholder Vote — Jul 26, 2024 Risk: low
  On July 25, 2024, Jazz Pharmaceuticals plc filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not disclos
• Jazz Pharmaceuticals Enters Material Definitive Agreement — Jul 22, 2024 Risk: medium
  On July 19, 2024, Jazz Pharmaceuticals plc entered into a material definitive agreement related to a financial obligation. The company, incorporated in Ireland,
• Jazz Pharma Appoints New CLO, Renews CFO Agreement — May 31, 2024 Risk: low
  Jazz Pharmaceuticals plc announced on May 31, 2024, changes in its executive team. The company appointed Renée Smith as Chief Legal Officer and General Counsel,
• Jazz Pharmaceuticals Files 8-K on Financials — May 1, 2024 Risk: low
  Jazz Pharmaceuticals plc filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• Jazz Pharma Files 8-K on Officer Changes and Compensation — Feb 27, 2024 Risk: medium
  This 8-K filing by Jazz Pharmaceuticals plc, filed on February 27, 2024, reports events that occurred on February 23, 2024. The filing indicates changes related
• Jazz Pharma 8-K Hints at Executive Changes, Compensation Updates — Feb 21, 2024 Risk: medium
  Jazz Pharmaceuticals plc filed an 8-K on February 21, 2024, reporting on Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointm
• Jazz Pharma Reports Material Agreement & New Financial Obligation — Jan 25, 2024
  Jazz Pharmaceuticals plc filed an 8-K on January 25, 2024, reporting an event on January 19, 2024, related to entering a material definitive agreement and creat
• Jazz Pharma Files 8-K: Routine Update, Nasdaq Listing Confirmed — Jan 8, 2024
  Jazz Pharmaceuticals plc filed an 8-K on January 8, 2024, to update its registration information, specifically confirming its status as a non-emerging growth co

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX